hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-17. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
The best-known brands labelled as cider are Golden Cap, Fizz, and Upcider. They typically contain 4.5–4.7% volume of alcohol. Virtually all Finnish "cider" is produced from fermented apple (or pear) juice concentrate mixed with water and is not cider as per the traditional description of the drink. Flavoured ciders, available in a large selection, are very popular and widely available in stores, with a variety of flavours ranging from forest berry to rhubarb and vanilla.
This application of bicalutamide was also under review by the FDA in the U.S. in 2002, but ultimately was not approved in this country. In Japan, bicalutamide is licensed at a dosage of 80 mg/day alone or in combination with a GnRH analogue for prostate cancer. The unique 80 mg dosage of bicalutamide used in Japan was selected for development in this country on the basis of observed pharmacokinetic differences with bicalutamide in Japanese men. Subsequent to negative findings of bicalutamide monotherapy for LPC in the EPC clinical programme, approval of bicalutamide for use specifically in the treatment of LPC was withdrawn in a number of countries including the U.K. (in October or November 2003) and several other European countries and Canada (in August 2003). In addition, the U.S. and Canada explicitly recommended against the use of 150 mg/day bicalutamide for this indication. The drug is effective for, remains approved for, and continues to be used in the treatment of LAPC and mPC, on the other hand. The patent protection of bicalutamide expired in the U.S. in March 2009 and the drug has subsequently been available as a generic, at greatly reduced cost. Bicalutamide was the fourth antiandrogen (and the third NSAA) to be introduced for the treatment of prostate cancer, following the SAA CPA in 1973 and the NSAAs flutamide in 1983 (1989 in the U.S.) and nilutamide in 1989 (1996 in the U.S.).
Primary structure the linear amino acid sequence of a protein, which chemically is a polypeptide chain composed of amino acids joined by peptide bonds. Profile (sequence context) a scoring matrix that represents a multiple sequence alignment of a protein family. The profile is usually obtained from a well-conserved region in a multiple sequence alignment. The profile is in the form of a matrix with each column representing a position in the alignment and each row one of the amino acids. Matrix values give the likelihood of each amino acid at the corresponding position in the alignment. The profile is moved along the target sequence to locate the best scoring regions by a dynamic programming algorithm. Gaps are allowed during matching and a gap penalty is included in this case as a negative score when no amino acid is matched. A sequence profile may also be represented by a hidden Markov model, referred to as a profile HMM. Profile (structural context) a scoring matrix that represents which amino acids should fit well and which should fit poorly at sequential positions in a known protein structure. Profile columns represent sequential positions in the structure, and profile rows represent the 20 amino acids. As with a sequence profile, the structural profile is moved along a target sequence to find the highest possible alignment score by a dynamic programming algorithm. Gaps may be included and receive a penalty. The resulting score provides an indication as to whether or not the target protein might adopt such a structure.
The HEVC encoder has 17 3G-SDI inputs and uses 17 boards for parallel processing with each board encoding a row of 7680 × 256 pixels to allow for real time video encoding. The HEVC encoder is compliant with draft 4 of the HEVC standard and has a maximum bit rate of 340 Mbit/s. The HEVC encoder was shown at the NHK Science & Technology Research Laboratories Open House 2013 that took place from May 30 to June 2. At the NHK Open House 2013 the HEVC encoder used a bit rate of 85 Mbit/s, which gives a compression ratio of 350∶1. On May 21, 2013, Microsoft announced the Xbox One, which supports 4K resolution (3840 × 2160) video output and 7.1 surround sound. Yusuf Mehdi, corporate vice president of marketing and strategy for Microsoft, has stated that there is no hardware restriction that would prevent Xbox One games from running at 4K resolution. On May 30, 2013, Eye IO announced that their encoding technology was licensed by Sony Pictures Entertainment to deliver 4K Ultra HD video. Eye IO encodes their video assets at 3840 × 2160 and includes support for the xvYCC color space. In mid-2013, a Chinese television manufacturer produced the first 50-inch UHD television set costing less than $1,000. On June 11, 2013, Comcast announced that they had demonstrated the first public U.S.-based delivery of 4K Ultra HD video at the 2013 NCTA show. The demonstration included segments from Oblivion, Defiance, and nature content sent over a DOCSIS 3.0 network.
=== Class I === Class I hydrophobins are characterised by having a quite diverse amino acid sequence between different types (with exception of the conserved cysteine residues), and compared to class II, they have long, varied inter-cysteine spacing. They form rodlets which have been identified as functional amyloids due to their amyloid-like characteristics as seen in X-ray diffraction studies and confirmed by their capacity to bind to amyloid-specific dyes such as Congo red and Thioflavin T. The formation of rodlets involves conformational changes that lead to formation of an extremely robust β-sheet structure that can only be depolymerised by treatment with strong acids. The rodlets can spontaneously form ordered monolayers by lateral assembly, displaying a regular fibrillary morphology on hydrophobic:hydrophilic interfaces. The most well characterised class I hydrophobin is EAS, which coats the spores of the fungus Neurospora crassa, followed by characterisation of DewA from Aspergillus nidulans.
Sources: en.wikipedia.org
=== COVID-19 pandemic === In June 2020, following Novak Djokovic's Adria Tour, several players tested positive for COVID-19. Due to his possible exposure, Zverev announced on Twitter that he would be following self-isolation procedures after testing negative for the virus. However, one week later, Zverev was captured on video at a party in Monaco, prompting criticism from fellow tennis players Nick Kyrgios and Katie Boulter.
Skoropadskyi himself supported the idea of reviving the Cossack class in Ukraine as a privileged social group personally loyal to the hetman. However, his initiative was viewed with skepticism by his ministers, and the law on re-establishment of Cossack administration in Ukraine was adopted only in October 1918, shortly before the hetman's resignation, and never realized. - During Skoropadskyi's tenure in power the Ukrainian State developed diplomatic ties with Cossack entities in the Kuban and Don region.
== Eukaryotic analogue == The complexity in bacterial responses appears to be in the number of proteins induced by oxidative stress. In mammalian cells, the number of proteins induced is small but the regulatory pathways are highly complex. The inducers of oxidative stress responses in bacteria appear to be either the oxidant itself or interaction of the oxidant with a cell component. Most mammalian cells exist in an environment where the oxygen concentration is constant, thus responses are not directly stimulated by oxidants. Rather, cytokines such as tumor necrosis factor, interleukin-1 or bacterial polysaccharides induce SOD synthesis and multigene responses. Recent work shows that superoxide is a strong tumor promoter that works by activation and induction growth-competence related gene products. Other factors involved in the antioxidant gene expression include an induction of calmodulin kinase by increase in Ca2+ concentrations. E. coli cells have revealed similarities to the aging process of higher organisms. The similarities include increased oxidation of cellular constituents and its target specificity, the role of antioxidants and oxygen tension in determining life span, and an apparent trade-off between activities related to reproduction and survival.
New chemical entities (NCEs, also known as new molecular entities or NMEs) are compounds that emerge from the process of drug discovery. These have promising activity against a particular biological target that is important in disease. However, little is known about the safety, toxicity, pharmacokinetics, and metabolism of this NCE in humans. It is the function of drug development to assess all of these parameters prior to human clinical trials. A further major objective of drug development is to recommend the dose and schedule for the first use in a human clinical trial ("first-in-human" [FIH] or First Human Dose [FHD], previously also known as "first-in-man" [FIM]). In addition, drug development must establish the physicochemical properties of the NCE: its chemical makeup, stability, and solubility. Manufacturers must optimize the process they use to make the chemical so they can scale up from a medicinal chemist producing milligrams, to manufacturing on the kilogram and ton scale. They further examine the product for suitability to package as capsules, tablets, aerosol, intramuscular injectable, subcutaneous injectable, or intravenous formulations. Together, these processes are known in preclinical and clinical development as chemistry, manufacturing, and control (CMC). Many aspects of drug development focus on satisfying the regulatory requirements for a new drug application. These generally constitute a number of tests designed to determine the major toxicities of a novel compound prior to first use in humans.
The offerings of Patient CROs (Clinical CROs) comprise more than 30 tasks addressing the clinical part of pharmaceutical development at the interface between drugs, physicians, hospitals, and patients, such as the clinical development and selection of lead new drug compounds. As clinical trials represent the largest expense in pharmaceutical research, the market for Patient CROs is larger than for their product counterparts. Thus, the sales of the top tier firms, such as Charles River Laboratories, Fortrea, Parexel, PPD, Quintiles Transnational, all USA, and TCG Lifescience, India, are in the $1–$2 billion range, whereas the largest Product CROs have revenues of a few 100 million dollars.
Sources: en.wikipedia.org
=== Detection in urine === Researchers found that humans who smoked 580 μg of the pure drug had urine salvinorin A concentrations of 2.4–10.9 μg/L during the first hour; the levels fell below the detection limit by 1.5 hours after smoking.
==== Examples of metabolism-based interactions ==== An example of this is shown in the following table for the CYP1A2 enzyme, showing the substrates (drugs metabolized by this enzyme) and some inductors and inhibitors of its activity:
Chloé Zhao's Nomadland wins three awards, including Best Picture, Best Director and Frances McDormand for Best Actress. David Fincher's Mank leads the nominations with ten, while Anthony Hopkins wins Best Actor for The Father (becoming the oldest winner in an acting category), Daniel Kaluuya Best Supporting Actor for Judas and the Black Messiah and Youn Yuh-jung Best Supporting Actress for Minari. Keeping in line with other award ceremonies reporting viewership declines, the telecast garners 10.4 million viewers according to Nielsen estimates, down 56% from the previous year and making the broadcast by far the lowest-rated in Oscar history. April 26 – COVID-19 pandemic – The CDC says that fully vaccinated Americans can go outside without wearing a mask unless they are in large crowds. April 27 – COVID-19 pandemic – Colorado surpasses 500,000 cases of COVID-19. April 28 2021 Joe Biden speech to a joint session of Congress: On the eve of his 100th day in office, President Biden gives his first address to a joint session of Congress encouraging them to pass $4 trillion worth of spending bills, including the American Jobs Plan and the American Families Plan, both part of his Build Back Better Plan. The South Dakota Supreme Court hears oral arguments on an appeal of a ruling which struck down South Dakota Amendment A, which would have legalized recreational cannabis in the state on July 1, 2021. April 30 COVID-19 pandemic Travel restrictions related to the COVID-19 pandemic – The White House announces the U.S.
It may consist of a single component or it may be a mixture of components. When the sample is treated in the course of an analysis, the phase or the phases containing the analytes of interest is/are referred to as the sample, whereas everything out of interest separated from the sample before or in the course of the analysis is referred to as waste. Solute – the sample components in partition chromatography. Solvent – any substance capable of solubilizing another substance, and especially the liquid mobile phase in liquid chromatography. Stationary phase – the substance fixed in place for the chromatography procedure. Examples include the silica layer in thin-layer chromatography Detector – the instrument used for qualitative and quantitative detection of analytes after separation. Chromatography is based on the concept of partition coefficient. Any solute partitions between two immiscible solvents. When one make one solvent immobile (by adsorption on a solid support matrix) and another mobile it results in most common applications of chromatography. If the matrix support, or stationary phase, is polar (e.g., cellulose, silica etc.) it is forward phase chromatography. Otherwise this technique is known as reversed phase, where a non-polar stationary phase (e.g., non-polar derivative of C-18) is used.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.